What is MA-8789?
MA-8789 is a new form of Immunotherapy. Because of its ability to utilize the body's natural immune cells, it is a potential weapon against cancer. The American Cancer Society has coined the phrase "the fourth modality" to refer to other Immunotherapy treatments.
Immunotherapeutic methods are currently being advanced at research centers across the U.S., with hopes that they will eventually reduce or eliminate the need for invasive procedures such as chemotherapy, radiation therapy, and surgery.
IPMD, Inc. is vigorously working towards the public availability of our product with the hope that in the near future, immunotherapy will be offered as a highly effective primary treatment option.
In vivo studies of MA-8789 indicate increases in the production of immune components such as CD3+, CD4+, CD8+, and CD8+CD25+ T lymphocytes, IgM+ B lymphocytes, natural killer (NK) cells, and cytokines such as IFN-γ and TNF-α. From these studies, a correlation has been established between MA-8789 treatment and immunostimulation, which we believe will aid tumor regression.
In vitro studies of MA8789 have been performed on human colon cancer cell line HT-29, lung cancer cell line NCI-H596, human hepatocellular carcinoma cell line SNU-398, and gastric carcinoma cell line SNU-719, showing efficacy with low survivorship of the transformed cells upon exposure of MA-8789.
The Immune system is a system within an organism which protects it from disease though the usage of biological structures and processes that identifies and kills pathogens and tumor cells.
The latest clinical studies and tests show that MA-8789 significantly improves immune system strength, preventing and curing many chronic illnesses. M8789 also holds incredible universal health benefits.